Renopharm Ltd. was founded in 2003 and is currently operating within the
NGT incubator in Nazareth. Renopharm has developed a unique,
proprietary, patent pending technology for the development of a novel group of
NO-donor drugs, based on NO attachment to natural chemical groups that are part
of physiological compounds or their natural metabolites. This novel drug
platform differs from current NO-based treatment in that it does not evoke
prodrug tolerance, a severe problem of NO based therapy that was until now
considered insolvable.
The Company is currently developing its Pet-8 as a drug candidate, and CNS-001 as a future drug candidate, intended for the treatment of hypertension and epilepsy, respectively. Renopharm's pipeline of future products is intended for treatment of other cardiovascular diseases and central nervous system (CNS) disorders, as well as Asthma, male sexual dysfunction and other diseases related to endothelial cell dysfunction or deficiencies of endogenous NO production. To protect these inventions and create a barrier to potential future competition, Renopharm has compiled an extensive portfolio of issued patents and pending patent applications, providing coverage of the Company's compound portfolio and multiple treatment methods.
So far, Renopharm has successfully completed a series of in-vitro and in-vivo studies, which provided substantial proof of concept of the safety and efficacy of the Company's lead drug candidate, Pet-8. IND submissions to the FDA are planned for Q2 2008, with Phase I clinical trials anticipated to commence in mid 2008.
The Need For NON-TOLERANT NITRIC OXIDE (NO) Drugs
Nitric oxide is a key biological messenger, playing a role in a variety of biological processes. Known as the 'endothelium-derived relaxing factor' (EDRF), it is biosynthesized from arginine and oxygen by various nitric oxide synthase (NOS) enzymes. Numerous disease states are associated with mal bioavailability of NO, therefore, NO plays a major role as a therapeutic strategy for many such conditions. The following diagram lists the diseases for which Renopharm is targeting its future drugs pipeline.
In
light of this pathobiology, augmentation of endogenous NO by exogenously
administered NO has provided the foundation for a broad field of drugs, and the
beneficial effects of administering NO-donors have been widely recognized.
However, treatment with conventional nitrate preparations, is typically limited
by their therapeutic bioavailability half-life, lack of selectivity, systemic
absorption accompanied by potentially adverse hemodynamic effects, and drug
tolerance, with the latter currently presenting the most challenging limit for
the clinical use of organic nitrite and nitrate esters. Renopharm has
decided to respond to this challenge, and will introduce the market with the
first-ever non-tolerant NO-donor antihypertensive drug.
Business Plan and business model:
We seek for all indications as well as for further indications which will emerge as a result of screening trials: strategic partners, partners for out-licensing, partners for JV of co-development to market & share of sales revenues.
Capital investment:
The Company is currently developing its Pet-8 as a drug candidate, and CNS-001 as a future drug candidate, intended for the treatment of hypertension and epilepsy, respectively. Renopharm's pipeline of future products is intended for treatment of other cardiovascular diseases and central nervous system (CNS) disorders, as well as Asthma, male sexual dysfunction and other diseases related to endothelial cell dysfunction or deficiencies of endogenous NO production. To protect these inventions and create a barrier to potential future competition, Renopharm has compiled an extensive portfolio of issued patents and pending patent applications, providing coverage of the Company's compound portfolio and multiple treatment methods.
So far, Renopharm has successfully completed a series of in-vitro and in-vivo studies, which provided substantial proof of concept of the safety and efficacy of the Company's lead drug candidate, Pet-8. IND submissions to the FDA are planned for Q2 2008, with Phase I clinical trials anticipated to commence in mid 2008.
The Need For NON-TOLERANT NITRIC OXIDE (NO) Drugs
Nitric oxide is a key biological messenger, playing a role in a variety of biological processes. Known as the 'endothelium-derived relaxing factor' (EDRF), it is biosynthesized from arginine and oxygen by various nitric oxide synthase (NOS) enzymes. Numerous disease states are associated with mal bioavailability of NO, therefore, NO plays a major role as a therapeutic strategy for many such conditions. The following diagram lists the diseases for which Renopharm is targeting its future drugs pipeline.
In
light of this pathobiology, augmentation of endogenous NO by exogenously
administered NO has provided the foundation for a broad field of drugs, and the
beneficial effects of administering NO-donors have been widely recognized.
However, treatment with conventional nitrate preparations, is typically limited
by their therapeutic bioavailability half-life, lack of selectivity, systemic
absorption accompanied by potentially adverse hemodynamic effects, and drug
tolerance, with the latter currently presenting the most challenging limit for
the clinical use of organic nitrite and nitrate esters. Renopharm has
decided to respond to this challenge, and will introduce the market with the
first-ever non-tolerant NO-donor antihypertensive drug.
Business Plan and business model:
We seek for all indications as well as for further indications which will emerge as a result of screening trials: strategic partners, partners for out-licensing, partners for JV of co-development to market & share of sales revenues.
Capital investment:
- Seed funding $538,000 by NGT, New Generation Technologies.
- We will be raising $5 million in the upcoming nine months for the purpose of taking our lead compound (Hypertension) through pre-clinical trials for the IND application and through Phase I of clinical trials, followed with forging corporate contacts & out-licensing or partnering agreements with midsize to big pharma.